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Abstract: Gastric cancer is ranked as the third death-causing cancer and one of the most incident malignancies 
worldwide. Although Helicobacter pylori is the most well-established risk factor for the development of this 
neoplasm, most of the infected individuals do not develop gastric cancer. Two of the main challenges faced by 
the world’s scientific community in the combat against gastric cancer are the unraveling of its pathogenesis 
and the identification of novel ways to bring down the mortality. Malignant cell invasion of the non-neoplastic 
adjacent tissue and metastasis are pivotal events during cancer development and progression. Both processes are 
facilitated by proteases capable of degrading components of the extracellular matrix, some of which have been 
associated to clinic-pathological aspects of the disease. Recent studies have suggested the possible connection 
between H. pylori and the expression of some of these proteases in gastric mucosa. This review summarizes the 
current knowledge about epidemiological, clinical and biological aspects of gastric cancer; it also discusses the 
main findings about the involvement of the plasminogen activation system in the development and progression 
of this disease, as well as its potential repercussions in the clinical setting. Rev. Biol. Trop. 66(1): 28-47. Epub 
2018 March 01.
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In 2012, 915 000 new cases, and 723 000 
deaths of gastric cancer (GC) were registered, 
making it one of the malignant tumors with the 
highest incidences and mortalities worldwide 
(Ferlay et al., 2015). To this date, few clinical 
parameters have proven its accurate early diag-
nosis and prognosis. This poses an important 
challenge, namely the identification of factors 
that can predict gastric carcinogenesis, and that 
can thus be used in clinical practice for preven-
tion, early diagnosis, prognosis and treatment.
Infection with Helicobacter pylori is the 
most recognized risk factor for developing 
GC (El-Omar et al., 2000b; Uemura et al., 
2001; Correa & Houghton, 2007). However, it 
remains an enigma that only a small percent-
age of people infected with H. pylori develop 
cancer. The final clinical outcome of the infec-
tion depends on complex interactions between 
characteristics of the infecting strain of the 
bacterium, the host immune response and envi-
ronmental factors (Kodaman et al., 2014). The 
composite and multifactorial etiology of GC 
presents a second challenge in the battle against 
the disease; the elucidation of the biological 
mechanisms underlying how and under which 
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circumstances H. pylori alter normal physi-
ological processes in such a way that sequential 
events culminate in the development of GC.
Remodeling of the extracellular matrix is 
a key event during malignant cell invasion and 
metastasis. It is principally mediated by two 
families of proteases: matrix metalloproteases 
(MMPs) and the plasminogen activation (PA) 
system (Egeblad & Werb, 2002; Danø et al., 
2005). The expression of some members of 
these families has been correlated to certain 
clinical and pathological parameters of GC. 
The understanding of the mechanisms that reg-
ulate invasion and metastasis of gastric tumors 
is of great importance for the possibility to pre-
dict the clinical course of the disease, optimize 
treatment and improve the life quality of the 
patients. This review provides a summary of 
epidemiological, clinical and biological aspects 
of GC, as well as an update of studies relating 
to the PA system in GC and its potential impli-
cations in clinical practice. Furthermore, recent 
findings that suggest the participation of H. 
pylori in the induction of some of the compo-
nents of the PA system are discussed.
Epidemiological aspects of gastric cancer
Gastric cancer is the fifth most common 
malignant tumor worldwide, following cancer 
of the lung, breast, colorectum and prostate 
(Ferlay et al., 2015). Incidence rates vary 
considerably depending primarily on age, sex 
and geographic location (Catalano et al., 2005; 
Forman & Burley, 2006). The majority of 
GC patients are over 50 years old when diag-
nosed and it affects two men for each woman 
(Catalano et al., 2005; Forman & Burley, 
2006; Brenner, Rothenbacher & Arndt, 2009). 
The most substantial variation in incidence is 
geographic, with high incidence in the Eastern 
parts of Asia, Eastern Europe and the Pacific 
coast of Latin America. In contrast, South 
Asia, Western Europe, North America, Austra-
lia and Africa, generally show low incidence 
(Bertuccio et al., 2009; Sierra, Cueva, Bravo & 
Forman, 2016).
In the last decades, the incidence of GC 
has fallen substantially in high- as well as 
low-risk areas. The reasons for this are not 
completely understood, although a concomi-
tant decrease in H. pylori prevalence is prob-
ably partly responsible (Parkin, Bray, Ferlay, 
& Pisani, 2005; Bertuccio et al., 2009). The 
decrease in incidence depends, however, on 
the histological type and anatomical location 
of the tumor. The intestinal subtype of GC has 
become much less frequent, whereas diffuse 
GC remains more or less stable (Parkin, 2001). 
Also, the rate of cancer of the cardias is stable, 
if not increasing, while distal adenocarcinomas 
in the lower part of the stomach are becoming 
less common (Kamangar, Dores, & Anderson, 
2006; Brenner et al., 2009).
With respect to mortality, GC occupies 
the third place on a global level, after lung and 
hepatic cancer (Ferlay et al., 2015). Mortal-
ity rates vary geographically and are particu-
larly high in developing countries, although a 
decrease has been observed during the last 
decades (Forman & Burley, 2006; Bertuccio 
et al., 2009; Ferlay et al., 2015; Sierra et al., 
2016). The five year survival rates are lower 
than 30 % in most countries due to the fact that 
the majority of cases are diagnosed at advanced 
stages when therapy is likely to fail (Forman 
& Burley, 2006). Studies in population groups 
with same ethnic background but dissimilar 
access to health services, suggest that environ-
mental and biological factors may also play an 
important role in explaining differences in mor-
tality and survival of gastric cancer between 
high- and low-risk countries, or developing and 
developed economies (Redaniel et al., 2009).
Histopathology
There are different systems for classifying 
GC by microscopic and histological charac-
teristics, namely the Japanese system, World 
Health Organization (WHO) classification and 
Lauren (Lauren, 1965; Japanese Gastric Can-
cer, 1998; Catalano et al., 2005). Among those 
mentioned, Lauren classification system is the 
most commonly used and divides GC into two 
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subtypes; intestinal and diffuse with important 
differences at the epidemiological, pathological 
and molecular levels (Lauren, 1965; Catalano 
et al., 2005; Dicken et al., 2005; Correa & 
Houghton, 2007; Nobili et al., 2011; Yasui et 
al., 2011). The reader is referred to Yakirevich 
and Resnick (2013) for a more detailed discus-
sion about the main differences between intes-
tinal and diffuse subtypes of GC, since this is 
out of the scope of the present review.
The anatomical location of the tumor in the 
stomach is also considered an important param-
eter in the classification of GC. Two major 
types can be distinguished; the tumors located 
in the distal region (non-cardia cancer) and in 
the proximal region (cardia cancer) (McColl, 
2006). These two anatomical subtypes are 
different in their etiology and epidemiology 
(Hansen et al., 2007; Derakhshan et al., 2008; 
Bertuccio et al., 2009; Wang et al., 2013). 
Some of the main differences between ana-
tomical subtypes of GC have been addressed 
with more detail by previously published excel-
lent reviews (McColl, 2006; Colquhoun et al., 
2015; Huang, Sun, Fang, Zhou, & Zou, 2016).
Risk factors
Among the risk factors for developing GC 
are diet and other features of life style, genetic 
predisposition of the individuals, infection with 
H. pylori and the chronic and persistent inflam-
mation that is generated in its presence (Cata-
lano et al., 2005; Fock et al., 2008; Peek, Fiske, 
& Wilson, 2010; Müller, Oertli, & Arnold, 
2011; Tramacere et al., 2012; Salama, Hartung, 
& Müller, 2013; Petrovchich & Ford, 2016). 
Diet has a dual role in the etiology of GC. 
Some foodstuffs, such as many fruits and veg-
etables, contain antioxidants that will reduce 
the formation of, or neutralize the activity 
of carcinogenic substances. On the contrary, 
other classes of food are sources of recognized 
carcinogens or their precursors (Tricker & Pre-
ussmann, 1991; Larsson Bergkvist, & Wolk, 
2006a; Larsson, Orsini, & Wolk, 2006b; Liu 
& Russell, 2008; Tsugane & Sasazuki, 2007).
Around 10 % of GC cases show famil-
ial aggregation, with two or three first grade 
relatives affected. This does not necessarily 
imply a genetic predisposition given that in 
addition to genetics, families share cultural 
and environmental influences (Brenner et al., 
2000). Nevertheless, there do exist a number 
of inheritable germ-line mutations and well-
characterized genetic syndromes that increase 
the risk of developing GC (Lynch, Grady, 
Suriano, & Huntsman, 2005; Oliveira, Seruca, 
& Carneiro, 2006; Petrovchich & Ford, 2016). 
Among the genetic variations that predispose 
for GC are germ-line mutations in the gene 
CDH1 (Guilford et al., 1998; Huntsman et al., 
2001; Carneiro, Oliveira, Suriano, & Seruca, 
2008; Hansford et al., 2015). This gene codes 
for the protein E-cadherin, which is expressed 
by epithelial cells and functions as an adhesion 
molecule (cell-cell interaction) thus inhibiting 
cellular invasion (Nagar, Overduin, Ikura, & 
Rini, 1996). GC associated with mutations in 
CDH1 exhibit an autosomal dominant inheri-
tance pattern with a penetration of more than 
70 %. Most of the GC cases attributed to muta-
tions in CDH1 are of the diffuse histological 
subtype, and the malignancy appears at young-
er age than GC cases not having germ-line 
mutations in this gene (Guilford et al., 1998; 
Huntsman et al., 2001; Carneiro et al., 2008; 
Carneiro, 2012; Hansford et al., 2015). 
Infection with H. pylori is one of the most 
prevalent bacterial infections. It is estimated 
that about half of the world’s population is 
infected (Parkin, 2006). H. pylori has been 
decisively linked to several gastric pathologies, 
such as atrophic gastritis, gastric and duodenal 
ulcers, MALT-lymphomas and GC. In recent 
years, the infection has also been inversely 
associated with a range of extra-gastric pathol-
ogies, like asthma, allergies and adenocarci-
noma of the esophagus (Blaser, 2008; Blaser, 
Chen, & Reibman, 2008; Chen & Blaser, 
2008; Imamura et al., 2010; Kyburz & Müller, 
2017). In spite of the aforementioned, the vast 
majority of infected people remain asymptom-
atic throughout their life. It is the combination 
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of bacterial, host and environmental factors 
that determine the ultimate clinical picture.
H. pylori is genetically highly variable and 
some strains are more strongly associated with 
GC. The most prominent are those that express 
the virulence factors VacA and Cag pathogenic-
ity island (Cag-PAI) (Yamaoka, 2010; Cover, 
2016). VacA is a cytotoxic protein which is 
expressed by the gene vacA. It induces the for-
mation of vacuoles that generate intracellular 
damage in the gastric epithelium (Odenbreit 
et al., 2000; Polk & Peek, 2010; Wroblewski, 
Peek, & Wilson, 2010). Although all strains of 
H. pylori produce VacA, the level of expres-
sion varies as a function of polymorphisms 
at three specific sites of the gene vacA: the 
signal region (s), the middle region (m) and the 
intermediate region (i) (Cover & Blanke, 2005; 
Rhead et al., 2007). Certain haplotypes of 
these polymorphic sites have been associated 
with GC (Rhead et al., 2007). The Cag-PAI-
positive strains possess a functional genetic 
region which contains approximately 30 genes 
that code for proteins that together make up a 
type IV secretion system. On average, func-
tional Cag-PAI is expressed by about 60 % 
of H. pylori strains but there are considerable 
variations in the prevalence of these strains 
between populations. The secretion system 
introduces a number of molecules, including 
the virulence factor CagA, into the cytoplasm 
of epithelial cells of the gastric mucosa (Shaf-
fer et al., 2011). Studies performed with trans-
genic mice have demonstrated that CagA is an 
oncoprotein capable of inducing cancer in the 
gastric epithelium (Ohnishi et al., 2008). Once 
in the cytoplasm, CagA is phosphorylated and 
this triggers downstream intracellular events 
such as cytoskeletal rearrangement, alterations 
in cellular polarity, expression of inflammatory 
mediators and activation of signaling pathways 
that promote cellular proliferation (Tan, Tomp-
kins, & Amieva, 2009; Polk & Peek, 2010; 
Hatakeyama, 2014; Naumann, Sokolova, Tegt-
meyer, & Backert, 2017). 
Other Cag-PAI-related pathogenicity 
mechanisms, independent of translocation and 
phosphorylation of CagA, have been described 
(Backert & Blaser, 2016; Naumann et al., 
2017). There is no known physical or func-
tional relation between vacA and cag-PAI. 
Nevertheless, strains that express virulent VacA 
usually contain functional Cag-PAI (Rhead et 
al., 2007; Basso et al., 2008). In addition to 
VacA and CagA, other, less well-characterized 
virulence factors of H. pylori have been associ-
ated to gastric pathology, for example BabA, 
SabA, OipA and DupA (Wroblewski et al., 
2010; Cover, 2016; Naumann et al., 2017).
Pathogenesis
The pathogenesis of GC is a complex and 
multifactorial process (Correa, 1992; Correa, 
2004; Hayakawa, Sethi, Sepulveda, Bass, & 
Wang, 2016). Infection with H. pylori, in com-
bination with environmental factors, results in 
superficial gastritis that, when persisting, devel-
ops into chronic gastritis, in many cases sub-
clinical. The majority of infected people never 
progress to severe pathology and many remain 
asymptomatic, whereas others develop gastric 
diseases that are not related to GC, such as duo-
denal ulcers. However, in some individuals, a 
severe and persistent inflammation evolves into 
chronic atrophic gastritis, characterized by the 
disappearance of glands and specialized cells 
in the gastric mucosa (Correa, 1992; Correa, 
2004). Chronic atrophic gastritis is considered 
to be a precancerous lesion, both for the intesti-
nal and diffuse subtypes (Correa, 1992; Correa, 
2004; Yuasa, 2003; Fox & Wang, 2007). The 
biological mechanisms underlying such diverse 
clinical outcomes resulting from infection with 
H. pylori are far from understood. It has been 
suggested that factors involved are the genetics 
of the infecting strain, polymorphic variants 
of genes regulating the host inflammatory 
response and the anatomical location of the 
tissue affected by chronic gastritis (El-Omar et 
al., 2000a; Alpízar-Alpízar, Pérez-Pérez, Une, 
Cuenca, & Sierra, 2005; Kodaman et al., 2014; 
Suerbaum & Michetti, 2002).
The subsequent step in the cascade of 
events leading towards intestinal GC is the 
transformation of the gastric epithelium into 
32 Rev. Biol. Trop. (Int. J. Trop. Biol. ISSN-0034-7744) Vol. 66(1): 28-47, March 2018
a morphology and histology that resembles 
intestinal epithelium, known as intestinal meta-
plasia (Correa, 1992; Correa, Piazuelo, & Wil-
son, 2010; Goldenring, Nam, & Mills, 2011; 
Suh et al., 2012). This new environment is not a 
favorable niche for H. pylori, which tends to be 
spontaneously eradicated from the transformed 
tissue (Valle, Kekki, Sipponen, Ihamaki, & 
Siurala, 1996; Kokkola et al., 2003). The con-
tinued progression of the lesions involves dys-
plasia, characterized by histological alterations 
of the epithelium such as nuclear atypia, loss of 
polarity and irregular shape of the gastric epi-
thelial cells. In advanced stages, the dysplastic 
cells acquire the capacity to migrate across 
basal membranes and surrounding tissue, thus 
completing the malignant transformation that 
culminates with the formation of early invasive 
carcinomas (Correa, 1992; Correa, 2004).
As for the diffuse subtype, no read-
ily detectable gastric preneoplastic lesions fol-
lowing chronic atrophic gastritis have been 
described and many aspects about its etiol-
ogy remain unknown. As already mentioned, a 
small number of cases of this particular subtype 
are attributed to mutations in the gene coding 
for E-cadherin, a genetic syndrome known as 
hereditary diffuse GC (Carneiro, 2012; Hans-
ford et al., 2015).
The remodeling of  
the extracellular matrix
A key feature of malignant transformation 
and progression is the invasion of malignant 
cells to the adjacent stroma and, in advanced 
stages, to distant sites (metastasis) (Hanahan 
& Weinberg, 2011; Lambert, Pattabiraman, 
& Weinberg, 2017). Metastasis is the result 
of a stepwise sequence involving the indi-
vidual or collective invasion of neoplastic cells 
locally, their entry into the vascular system 
(intravasation) and survival in circulation, the 
extravasation at distant sites and, finally, the 
establishment and colonization by dissemi-
nated tumor cells in new tissues and organs 
(Valastyan & Weinberg, 2011; Lambert et al., 
2017). The degradation of the extracellular 
matrix, or remodeling of tissue, is essential in 
several phases of this process. This remodel-
ing is mediated by proteases that are capable 
of degrading virtually any component of the 
extracellular matrix (Danø et al., 1999; Kessen-
brock, Plaks, & Werb, 2010). These proteases 
belong to two main groups: the MMPs and the 
PA system. This review is focused on the PA 
system and its relation to gastric carcinogenesis.
The plasminogen activation system
This system comprises a few proteins that 
by acting in sequence lead to the conversion of 
zymogenic plasminogen into its active enzymat-
ic form, plasmin. Plasmin is a serine-protease 
capable of breaking down components of the 
extracellular matrix such as fibrin, fibronectin, 
laminins and vitronectin (Liotta et al., 1981). 
Other substrates of plasmin are TGFβ, the 
zymogenic form of its own activator (pro-uPA) 
and some pro-MMPs (Lamarre, Vasudevan, & 
Gonias, 1994; Lijnen, 2002). Plasminogen is 
activated after proteolytic cleavage by either 
of the two well-characterized serine-proteases: 
urokinase-type and tissue-type plasminogen 
activators (uPA and tPA, respectively). tPA is 
relevant in generating plasmin for vascular 
fibrinolysis, whereas uPA plays a crucial role 
in processes involving tissue remodeling, both 
in homeostasis and pathologies like cancer 
(Kristensen et al., 1984; Andreasen, Egelund, 
& Petersen, 2000); uPA is, therefore, respon-
sible for the conversion of plasminogen into 
plasmin in the context of tumor invasion. This 
occurs after binding of pro-uPA to its cognate 
membrane receptor, uPAR, which results in 
uPA activation and, subsequently, plasminogen 
activation in the surface of uPAR expressing 
cells (Ploug, 2003). The activity of tPA and 
uPA is mainly controlled by two endogenous 
inhibitors, PAI-1 and PAI-2, the former being 
the primary regulator of the plasminogen acti-
vation in cancer (Andreasen, Georg, Lund, Ric-
cio, & Stacey, 1990; Behrendt, List, Andreasen, 
& Danø, 2003). The expression levels of uPA, 
uPAR and PAI-1 under normal homeostatic 
conditions is almost undetectactable, however 
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in cancer and other pathologies, their expres-
sion increase significantly (Kriegbaum et al., 
2011). The stepwise process leading to plas-
minogen activation is summarized in Fig. 1.
The PA system is involved in several 
key aspects of cancer development and pro-
gression, including local invasion, metastasis, 
tumor growth and angiogenesis (Ossowski, 
Russo-Payne, & Wilson, 1991; Bugge et al., 
1998; Bajou et al., 2001; Binder & Mihaly, 
2008). Some members of the system may 
also elicit important cellular and physiological 
effects independent of their role in plasmino-
gen activation. By interacting with integrins, 
uPAR induces activation of cell signaling path-
ways related to increased proliferative, inva-
sive and metastatic potential (Yu, Kim, & 
Ossowski, 1997; Blasi & Carmeliet, 2002; Liu, 
Aguirre-Ghiso, Estrada, & Ossowski, 2002; 
Smith & Marshall, 2010). PAI-1 plays a seem-
ingly important role in cancer cell detachment, 
which is mediated by its binding to extracel-
lular matrix proteins such as vitronectin and 
type-1 collagen that may ultimately lead to 
enhanced dissemination of these cells (Czekay, 
Aertgeerts, Curriden, & Loskutoff, 2003). In 
general, uPA, uPAR and PAI-1 are mainly 
expressed by non-neoplastic cells of the peri-
tumoral stromal compartment and, to lesser 
extent, by cancer cells located at the invasive 
front of the malignant growth (Lund, Ille-
mann, Thurison, Christensen, & Høyer-Han-
sen, 2011), being there where their pro-invasive 
and pro-metastatic effects are exerted.
The expression of the three components of 
the PA system is generally increased in cancer 
and this has proven to be of prognostic rel-
evance. The association between high levels of 
uPA, uPAR and PAI-1 and poor prognosis has 
been convincingly demonstrated in colorectal, 
breast, ovarian, prostatic and gastroesophageal 
cancer (Duffy et al., 1990; Grøndahl-Hansen 
et al., 1993; Pedersen et al., 1994a; Pedersen 
et al., 1994b; Grøndahl-Hansen et al., 1995; 
Stephens et al., 1999; Foekens et al., 2000; 
Høyer-Hansen & Lund, 2007; Almasi, Høyer-
Hansen, Christensen, & Pappot, 2009; Almasi 
et al., 2011; Lund et al., 2011; Brungs et al., 
2017). Using immunohistochemistry, it was 
demonstrated that uPAR is a factor that predicts 
Fig. 1. The members of the plasminogen activation system and the mechanism of plasminogen activation: Binding of 
pro-uPA to its specific receptor, uPAR, causes the conversion of plasminogen into plasmin, which is achieved by proteolytic 
cleavage. Newly-formed plasmin molecules further catalyze the conversion of pro-uPA into uPA, and this, in turn, 
accelerates plasminogen activation. PAI-1 inhibits this sequential series of events by binding to the uPA-uPAR complex. 
Plasmin can degrade several components of the extracellular matrix, but it can also activate some MMPs.
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patients overall survival in gastroesophageal 
cancer (Laerum et al., 2012). The relevance of 
uPAR as prognostic biomarker has also been 
suggested, by using immunohistochemical 
means, in oral squamous cell carcinoma (Lind-
berg, Larsson, & Nielsen, 2006; Bacchiocchi 
et al., 2008). Moreover, it has been shown that 
presence of uPAR-expressing neoplastic cells 
in the bone marrow of GC patients is a prog-
nostic parameter (Heiss et al., 1995a; Heiss et 
al., 2002). Therefore, it is clear that members of 
the PA system are potentially interesting candi-
dates to be used in clinical practice as biomark-
ers to evaluate the prognosis of cancer patients.
The plasminogen activation system  
and gastric cancer
Several investigations have studied the 
expression pattern of the members of PA sys-
tem in GC, as well as the mechanisms of induc-
tion and their clinical relevance as prognostic 
biomarkers. Most of these reports have focused 
on uPAR, since this receptor is crucial for the 
initiation of the sequential series of events that 
ultimately result in the activation of plasmino-
gen. Interestingly, it has been suggested that H. 
pylori may induce the expression of uPAR in 
non-neoplastic gastric epithelial cells (Alpízar-
Alpízar et al., 2010).
The expression pattern of the components 
of PA system in GC is very similar to what has 
been reported in other cancer types. The three 
members are mainly expressed by accessory 
(non-neoplastic) cells within the stroma sur-
rounding the tumor growth, both in intestinal 
and diffuse subtype (Fig. 2) (Alpízar-Alpízar et 
al., 2010). Macrophages located at the invasive 
front of the tumors are the cell population with 
the strongest contribution to the uPAR expres-
sion in GC. Myofibroblasts and endothelial 
cells at the same location also express uPAR, 
but their expression is not as pronounced as 
that of macrophages (Alpízar-Alpízar et al., 
2010). Neutrophils are the fourth accessory cell 
type of the stromal compartment of the tumors 
that is positive for uPAR (Alpízar-Alpízar et 
al., 2010). Neutrophils, however, express this 
receptor constitutively (Plesner et al., 1994a; 
Plesner et al., 1994b), in contrast to macro-
phages, myofibroblasts and endotelial cells in 
which uPAR is induced by not yet identified 
factors that are present in the tumor microenvi-
ronment. The upregulation of uPAR in this area 
often generates an “intensity gradient”, which 
irradiates from the very front of the invasive 
tumor and dilutes out from this location (Fig. 
2). This phenomenon can also be seen in other 
cancer types, in particular colorectal cancer 
(Kriegbaum et al., 2011; Lund et al., 2011). 
Although the induction of uPA and PAI-1 in 
GC is not as well-documented as that of uPAR, 
these two molecules are primarily expressed 
by myofibroblasts at the invasive front of the 
malignant growth (Fig. 2), similar to what has 
been observed in other cancer sites, including 
colorectal neoplasm (Illemann et al., 2009; 
Lund et al., 2011). 
uPAR expression in cancer cells has also 
been reported in GC (intestinal and diffuse 
subtype), particularly in detached cancer cells 
found within the tumor stromal microenviron-
ment (Fig. 2) (Migita et al., 1999; Alpízar-Alpí-
zar et al., 2012; Alpízar-Alpízar et al., 2010). 
These uPAR-positive malignant cells are espe-
cially interesting in the context of tumor pro-
gression, since studies in colorectal cancer 
show that some of these cells co-express uPAR 
and its cognate ligand (uPA), as well as other 
molecules associated to increased invasive 
potential such as laminin-5 (Pyke et al., 1995; 
Illemann et al., 2009). It is speculated that 
these cells are particularly prone to invade and 
metastasize, which is also facilitated because of 
their increased potential to migrate (Chaurasia 
et al., 2006; Gårdsvoll & Ploug, 2007; Madsen 
& Sidenius, 2008). In fact, studies performed 
in GC indicate that the expression of uPAR in 
malignant cells per se emerges as a feature of 
more aggressive tumors (Heiss et al., 1995a; 
Heiss et al., 2002; Alpízar-Alpízar et al., 2012). 
For example, studies performed in bone mar-
row aspirates obtained preoperatively from 
gastric cancer patients reveal that the presence 
of disseminated uPAR-positive tumor cells in 
bone marrow is strongly associated to poor 
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overall survival, compared to patients with 
either uPAR-negative disseminated cells or no 
metastatic cells at all in bone marrow (Heiss et 
al., 1995a; Heiss et al., 2002). Also, Alpízar-
Alpízar et al. (2012) studied the contribution 
of the different uPAR-expressing cell types 
that are found in the malignant growth to the 
overall survival of GC patients, revealing that 
the presence uPAR-positive cancer cells at the 
invasive front of the tumors can predict the sur-
vival of patients (Alpízar-Alpízar et al., 2012). 
Less that 10 % of the cancer cells show expres-
sion of uPAR in GC (Alpízar-Alpízar et al., 
2010; Alpízar-Alpízar et al., 2012), however, as 
already mentioned, this fraction probably repre-
sents a more malignant subpopulation of cancer 
cells. The prevalence of uPAR-positive cancer 
cells may then be regarded as an indication 
Fig. 2. uPAR, PAI-1 and uPA expression in gastric cancer: uPAR expression at the invasive front of the tumor growth 
in GC is illustrated by immunohistochemical staining with a polyclonal antibody against human uPAR (panels A and B). 
uPAR expression is strongly induced in the tumor stroma bordering the invasive front of tumor growth (panel A: Ca: 
cancer, Est: stroma). In GC lesions it is possible to observe uPAR expression in cancer cells (arrows in panel B), especially 
those localized at the invasive front of malignant growth, both in the intestinal (not shown in the figure) and in the diffuse 
subtype of GC (panel B). PAI-1 is also expressed in GC lesions, as evidenced by carrying out immunohistochemistry with 
a polyclonal anti-human PAI-1 antibody (panel B). PAI-1 is expressed by elongated stromal cells, similar to fibroblasts 
(arrows in panel C), which in colon cancer have been identified as myofibroblasts. PAI-1 positive cell are localized in close 
proximity or in direct contact with cancer cells invading the stroma (panel B). uPA expression is seen by performing in situ 
hybridization in GC lesions with specific antisense probes against uPA mRNA, which is observed as black granular deposits 
(arrows in panel D). uPA expression is also prominent in the tumor microenvironment, specifically in accessory cells found 
in the tumor stroma bordering tumor growth (panel D).
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of more aggressive gastric malignant tumors, 
highlighting the potential prognostic usefulness 
of this parameter.
The factor(s) inducing the expression of 
the members of PA system have not been 
identified, but some studies, most of them 
performed in vitro, have proposed a number of 
mechanisms by which this can occur. Several 
signaling pathways lead to the activation of 
transcription factors that recognize specific 
sequences within the promoter region of the 
gene coding for uPAR (PLAUR), thus induc-
ing its expression in cancer lesions. Ras-ERK 
MAPK pathway is among the ones frequently 
active in cancer (Bamford et al., 2004). A tran-
scription factor often activated by ERK kinase 
is AP-1, which has been implicated in the 
transcriptional regulation of uPAR (Lengyel 
et al., 1996b). In addition, the expression of 
uPAR seems to be upregulated in response to 
hypoxia, and this is associated to the bind-
ing of hypoxia-inducible factor-1α (HIF1α) 
to a hypoxia-response element (HRE) that is 
present in the promoter of PLAUR (Krishnam-
achary et al., 2003). The nuclear factor-κB 
(NF-κB) has also been associated to the activa-
tion of uPAR expression by either, an indirect 
mechanism that involves transcriptional activa-
tion of the gene coding for HIF1α (Rius et al., 
2008), or direct binding of NF-κB to specific 
sequences of the promoter of PLAUR (Wang 
et al., 2000). The promoter of PLAUR also has 
sequences that are specifically recognized by 
the transcription factors SP1 and AP2, which 
have been implicated in the induction of uPAR 
expression in human cancers, including GC 
(Schewe et al., 2003; Schewe et al., 2005; Mau-
rer et al., 2007). Finally, some studies indicate 
that the expression of uPAR, uPA and PAI-1 in 
accessory cells of the tumor stroma is induced 
by growth factors and cytokines, among them 
several members of the fibroblast growth factor 
(FGF) family, TNFα and TNFβ (Yoshida et al., 
1996; Sieuwerts, Martens, Dorssers, Klijn, & 
Foekens, 2002).
Studies performed with GC cell lines coin-
cide with most of the above-mentioned mecha-
nisms of induction for the components of the 
PA system in cancer. An example of this are 
the investigations concluding that both epi-
dermal growth factor (EGF) and macrophage 
stimulating protein (MSP) induce the expres-
sion of uPAR via signaling pathways involv-
ing ERK-1/2, AP-1 and NF-κB (Baek et al., 
2008; Park, Park, Khoi, Joo, & Jung, 2011). 
The activation of ERK, as a result of the EGF 
binding to its membrane receptor, c-MET, is 
also implicated in the upregulation of uPA in 
GC cell lines (Lee et al., 2006). Other mol-
ecules that have been studied in relation to the 
induction of uPAR and uPA in GC cell lines are 
interleukin-1β (IL-1β), lysophosphatidic acid 
(LPA) and macrophage inhibitory cytokine 
(MIC-1), although the evidence is less conclud-
ing in these cases (Iwamoto et al., 2003; Lee et 
al., 2003; Kim et al., 2008).
The relation between expression of com-
ponents of the PA system, especially uPAR, and 
clinico-pathological aspects has been explored 
in GC (Heiss et al., 1995b; Kawasaki et al., 
1998; Zhao, Wang, Qu, Huang, & Wang, 2002; 
Kaneko, Konno, Baba, Tanaka, & Nakamura, 
2003; Lee et al., 2004; Zhang, Zhao, Ru, & Ma, 
2006; Kita et al., 2009; Alpízar-Alpízar et al., 
2012; Guo, Ling, Ma, Zhou, & Zhao, 2015). 
One of the parameters consistently correlated 
with the expression of the members of this 
system is patient survival, which is generally 
shorter in patients with elevated expression, 
particularly of uPAR (Table 1). This has been 
determined at the mRNA and protein level, 
using different types of biological material 
and methodological approaches (Table 1). In 
addition to patient survival, the expression of 
members of the PA system has been correlated 
to tumor size, differentiation grade, vascu-
lar and lymphatic invasion and lymph node 
involvement, among others (Kawasaki et al., 
1998; Kaneko et al., 2003; Zhang et al., 2006; 
Guo et al., 2015). In most of these studies, the 
relation between expression of components of 
the PA system and clinico-pathological vari-
ables is analyzed regardless of the type and 
localization of the cells expressing uPAR, uPA 
or PAI-1 in the tumor microenvironment. This 
is mainly because most of the methodologies 
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employed for the experimental quantification 
of the components do not allow this type of 
stratification. However, finely-tuned analysis 
of the relation between clinico-pathological 
parameters and subpopulations of cells that 
express uPAR, uPA and PAI-1 is highly desir-
able, because not all the cells within the tumor 
microenvironment make the same contribution 
TABLE 1
Studies performed in gastric cancer to assess the prognostic value of uPAR, uPA and PAI-1 
and their relation to other clinico-pathological parameters
Author n (patients) Biologic Material Method of measurement Main finding
Alpízar-Alpízar 
et al., 2012
95 Paraffin-embedded 
tissue
Immunohistochemistry uPAR expression in cancer cells is 
associated to poor overall survival. 
It is a parameter independent of 
clinical variables.
Heiss et al., 2002 156 Bone marrow Immunohistochemistry Presence of uPAR-positive cancer 
cells in bone marrow is associated 
to shorter progression-free and 
overall survival. It is a parameter 
independent of clinical variables.
Heiss et al., 1995b 203 Paraffin-embedded 
tissue
Immunohistochemistry Elevated expression of uPAR, uPA 
and PAI-1 in neoplastic tissue is 
associated to shorter recurrence-free 
and overall survival, as well as to 
other clinico-pathological variables.
PAI-1 expression is a parameter 
independent of clinical variables.
Kaneko et al., 2003 101 Paraffin-embedded 
tissue
Immunohistochemistry High uPAR and uPA expression in 
neoplastic tissue is associated to 
shorter overall survival. uPA is a 
parameter independent of clinical 
variables.
Kawasaki et al., 1998 91 Paraffin-embedded 
tissue
Immunohistochemistry 
and in situ hybridization
High uPAR and PAI-1 expression, 
simultaneously, correlates with 
venous and lymphatic invasion, 
lymphatic metastasis and depth of 
invasion (advanced cancer).
Kita et al., 2009 846 Bone marrow and 
peripheral blood
qRT-PCR Elevated uPAR mRNA levels in 
peripheral blood are an independent 
prognostic parameter for distant 
metastasis.
Lee et al., 2004 35 Fresh tissue RT-PCR y Northern blot High uPAR expression in neoplastic 
tissue is associated to lower overall 
survival.
Zhang et al., 2006 105 Paraffin-embedded 
tissue
in situ hybridization Elevated uPAR and uPA expression 
is associated to shorter overall 
survival.
Zhao et al., 2002 76 Plasma ELISA High uPAR expression correlates to 
lymph-node involvement and distant 
metastasis.
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to cancer growth and progression. This idea is 
supported by immunohistochemistry studies 
showing that uPAR-expressing cancer cells 
are particularly informative to predict patient 
survival in GC (Heiss et al., 2002; Alpízar-
Alpízar et al., 2012). Overall, according to 
the existing evidence, uPAR emerges as the 
member of the PA system with more potential 
to be used in the clinical practice as prognostic 
biomarker in GC.
Plasminogen activation system  
and Helicobacter pylori
H. pylori has been related to induction 
of uPAR. Several in vitro studies have found 
that the expression of uPAR is upregulated in 
cancer and gastric epithelial cell lines when 
co-cultured with H. pylori (Guillemin, Salama, 
Tompkins, & Falkow, 2002; Sepulveda et al., 
2002; El-Etr, Mueller, Tompkins, Falkow, & 
Merrell, 2004; Iwamoto et al., 2005; Kim et al., 
2005; Kim et al., 2007; Iwamoto, Mizokami, 
Takahashi, Matsuoka, & Matsuzaki, 2008). 
This phenomenon has also been documented 
in vivo, specifically in non-neoplastic tissue 
(adjacent to the tumor growth) obtained from 
GC patients (Alpízar-Alpízar et al., 2010), as 
well as in gastric biopsies from patients that 
have no cancer but are infected with the bac-
terium (Kenny et al., 2008). In addition, one 
study reported a significant correlation between 
uPAR expression in neoplastic tissue and pres-
ence of H. pylori in adjacent non-neoplastic 
tissue (Beyer et al., 2006). More recently, the 
possible link between H. pylori and uPAR was 
systematically investigated in a mouse model 
of H. pylori-induced gastritis (Alpízar-Alpízar 
et al., 2013). According to this study, uPAR 
expression in foveloar epithelial cells (mucus-
producing cells) is upregulated very early in 
response to the infection and increases progres-
sively during the course of infection. The study 
also indicates that eradication of H. pylori 
infection by antimicrobial therapy causes a 
regression of uPAR expression to its physi-
ological baseline levels, comparable to what is 
observed in non-infected mice (Alpízar-Alpízar 
et al., 2013). Additional experiments in this 
experimental model suggest that uPAR expres-
sion is directly induced by the bacterium (Alpí-
zar-Alpízar et al., 2013 and Alpízar-Alpízar, 
unpublished). Nevertheless, it cannot be totally 
excluded the possibility that uPAR induction 
in the gastric epithelium occurs as a secondary 
event, resulting from the inflammatory reaction 
mounted in response to H. pylori infection.
The mechanisms underlying the induction 
of uPAR in gastric epithelium in response to 
H. pylori infection are far from being clear; 
however, several studies have shed some light 
in relation to this. It is well known that H. 
pylori infection can lead to the activation of 
the transcriptional regulator NF-κB, by several 
mechanisms (Rieke, Papendieck, Sokolova, 
& Naumann, 2011; Sokolova, Maubach, & 
Naumann, 2014; Naumann et al., 2017). On 
the other hand, NF-κB is regarded as a very 
likely candidate for inducing the expression 
of uPAR in cancer (Wang et al., 2000; Baek et 
al., 2008). Thus, NF-κB activation in response 
to H. pylori infection could at least partially 
explain the upregulation of uPAR expression 
that is observed in epithelial cells of H. pylori-
colonized mucosa, both in human and mouse. 
Despite the existence of some in vitro studies 
indicating that NF-κB is implicated in the H. 
pylori-driven induction of uPAR (Kim et al., 
2007), no experimental evidence has been 
generated in vivo to substantiate this finding. 
AP-1, another transcription factor commonly 
associated to the induction of uPAR (Lengyel 
et al., 1996b; Baek et al., 2008), is activated 
as a result of H. pylori infection (Naumann et 
al., 2017). This means that AP-1 may also be a 
factor implicated in the induction of uPAR in 
response to this infection (Kim et al., 2005). A 
commonality of the induction of uPAR medi-
ated by NF-κB or AP-1 is that ERK signaling 
pathway can lead to activation of both tran-
scriptional regulators (Lengyel et al., 1996a; 
Baek et al., 2008). If taking into consideration 
that ERK signaling pathway is often manipu-
lated by H. pylori (Naumann et al., 2017), 
this pathway becomes an obvious study target 
to gain further insight about the mechanism 
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of induction of uPAR in the gastric epithelium 
colonized with H. pylori.
Conclusions and perspectives
In GC, the expression of members of the 
PA system is elevated, particularly for uPAR, 
therefore, their potential clinical utility as prog-
nostic biomarkers in this cancer is evident. The 
clinical use of some components of this system 
has been validated in other cancer types, as it 
is the case for uPA and PAI-1, which has been 
recommended by the American Society of 
Clinical Oncology (ASCO) since 2007, for the 
identification of lymph node-negative breast 
cancer patients that would benefit from adju-
vant treatment (Jänicke et al., 2001; Look et 
al., 2002; Harris et al., 2007). Given that uPAR 
is a factor that promotes local and distant dis-
semination of malignant cells, its utilization 
as prognostic parameter could contribute to 
the identification of GC patients with more 
aggressive phenotypes of the disease and, 
consequently, higher risk of either recurrence 
or metastasis. GC patients with elevated uPAR 
expression may benefit from adjuvant therapies 
that compensate for their higher risk of relapse 
and metastasis, especially those in which the 
disease is diagnosed at an early stage.
In spite of the above-mentioned, most of 
the investigations carried out thus far about 
uPAR and its prognostic value in GC are small 
and retrospective. Therefore, studies, ideally 
prospective ones, with large sample size are 
needed to validate the prognostic impact of 
uPAR in this malignancy. This is especially 
relevant when taking into account that the mor-
tality attributed to GC is very high and only a 
few parameters have proven to have prognostic 
value, most of them are clinical variables not 
related to the biology of the disease.
The suitability of some members of the 
PA system as cancer diagnostic biomarkers 
has been proposed (Lund et al., 2011). Studies 
in prostatic and ovarian cancers demonstrate 
that the measurement of uPAR protein levels 
in blood can discriminate very well between 
benign and malignant tumors (Piironen et al., 
2006; Henic, Borgfeldt, Christensen, Casslén, 
& Høyer-Hansen, 2008). The diagnostic value 
of uPAR has not been explored at all in GC, 
but this evaluation is important, especially in 
early stage tumors, because this may translate 
into a better chance of curing the disease and, 
consequently, in a reduction in the mortality 
rates for this neoplasm.
The potential link between H. pylori and 
uPAR induction may represent a novel find-
ing in the genesis of GC and other pathologies 
associated to this bacterial infection. More 
specifically, this observation may contribute to 
explain, from a molecular and cellular perspec-
tive, how it is that H. pylori infection is associ-
ated to several clinical outcomes. Particularly, 
interesting is the fact that this bacterium is 
inducing in non-neoplastic gastric mucosa a 
protein that until now has been implicated 
in processes related to late stages of cancer 
development and progression and, in addition, 
has been correlated to the prognosis of cancer 
patients in general. It is, however, necessary 
to clarify a series of questions that arise, some 
related to the cellular and molecular mecha-
nisms by which H. pylori induces uPAR, others 
regarding the implications of this phenomenon 
in the pathological context. First, it is important 
to determine whether uPAR expression in the 
apical membrane of gastric epithelial cells is 
related to strains harboring certain virulence 
factors or particular features. Second, it is rel-
evant to clarify the signaling mechanisms that 
govern this phenomenon. Finally, is it neces-
sary to understand whether the presence of 
uPAR in the surface of gastric epithelial cells 
confers some survival benefit to H. pylori and 
to what extent this affects the development of 
cancer or other gastric pathologies. Addressing 
these aspects is relevant since the upregula-
tion of uPAR in non-neoplastic gastric mucosa 
could imply that these people have an increased 
risk of developing GC, so it would have 
clinical utility as parameter for prevention and 
early detection, or to decide whether a patient 
requires H. pylori eradication therapy.
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RESUMEN
La importancia del sistema activador de plasminó-
geno en la patogénesis y progresión del cáncer gástrico. 
El cáncer gástrico es la tercera causa de muerte por cáncer 
a nivel mundial y uno de los más incidentes. A pesar de que 
la infección por Helicobacter pylori es el factor de riesgo 
más reconocido para el desarrollo de esta neoplasia, la 
mayoría de personas infectadas con la bacteria no desarro-
lla la enfermedad. Dos de los principales desafíos a los que 
actualmente se enfrenta la comunidad científica mundial 
en la lucha contra el cáncer gástrico son el esclarecimiento 
de la patogénesis y la identificación de nuevos parámetros 
que contribuyan a disminuir la mortalidad. La invasión de 
las células malignas al tejido no neoplásico adyacente y la 
metástasis son eventos claves durante el desarrollo y pro-
gresión del cáncer. Lo anterior es facilitado por proteasas 
capaces de degradar los componentes de la matriz extrace-
lular, algunas de las cuales han sido asociadas con aspectos 
clínico-patológicos de la enfermedad. Estudios recientes 
han sugerido la posible relación entre la bacteria H. pylori 
y la inducción en mucosa gástrica de algunas de estas pro-
teasas. Esta revisión resume conocimientos actuales sobre 
aspectos epidemiológicos, clínicos y biológicos del cáncer 
gástrico; también discute los principales hallazgos en torno 
a la participación del sistema activador de plasminógeno en 
el desarrollo y progresión del mismo, así como sus poten-
ciales repercusiones en la práctica clínica.
Palabras clave: Cáncer gástrico; Helicobacter pylori; sis-
tema activador de plasminógeno; uPAR; metástasis.
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